Ikeda, T. Drug-induced idiosyncratic hepatotoxicity: prevention strategy developed after the troglitazone case. Drug Metab Pharmacokinet. 2011; 26(1):60–70.
Akman, SA, et al. Liver transplantation for acute liver failure due to toxic agent ingestion in children. Pediatr Transplant. 2009 Dec; 13(8):1034–1040. [Epub 2009 Feb 6. Erratum in: Pediatr Transplant. 14(8):1041, 2010].
Giri, S, et al. Hepatotoxicity and hepatic metabolism of available drugs: current problems and possible solutions in preclinical stages. Expert Opin Drug Metab Toxicol. 2010; 6(8):895–917.
Kim, HR, et al. Occupational hepatic disorders in Korea. J Korean Med Sci. 2010; 25(Suppl):S36–S40.
Senior, JR. Unintended hepatic adverse events associated with cancer chemotherapy. Toxicol Pathol. 2010; 38(1):142–147.
Teschke, R. Kava hepatotoxicity: pathogenetic aspects and prospective considerations. Liver Int. 2010; 30(9):1270–1279.
Carlsen, KM, et al. Toxic hepatitis induced by infliximab in a patient with rheumatoid arthritis with no relapse after switching to etanercept. Clin Rheumatol. 2009; 28(8):1001–1003.
Gemcitabine: cutaneous, hepatic and vascular disorders. Prescrire Int. 2009; 18(101):122.
Grattagliano, I, et al. Biochemical mechanisms in drug-induced liver injury: certainties and doubts. World J Gastroenterol. 2009; 15(39):4865–4876.